HOTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hoth Therapeutics Inc (HOTH) is not a strong buy for a beginner, long-term investor at this time. The stock shows mixed technical indicators, lacks positive financial performance, and has no strong proprietary trading signals. While there are some positive news catalysts, the company's fundamentals and lack of significant trading trends suggest a cautious approach.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 67.95, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels, with a pivot at 0.621, R1 at 0.732, and R2 at 0.801.
Hoth Therapeutics' HT-VA drug showed significant promise in improving liver fat metabolism and outperformed Novo Nordisk's semaglutide in key metabolic markers. This resulted in significant short-term price surges.
The company recently announced a $2 million stock offering, which caused a slight decline in stock price. Additionally, the financials show negative EPS growth and no revenue generation.
In 2025/Q4, the company reported no revenue growth (0% YoY), a net income loss of -$2,688,189 (up 12.81% YoY), and a significant drop in EPS (-48.48% YoY). Gross margin remains at 0%.
No recent analyst ratings or price target changes available.
